Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $43.17.
ORKA has been the topic of a number of recent research reports. Stifel Nicolaus began coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $49.00 target price on the stock. Leerink Partnrs raised shares of Oruka Therapeutics to a "strong-buy" rating in a report on Tuesday, September 17th. Leerink Partners began coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They set an "outperform" rating and a $44.00 price target on the stock. TD Cowen assumed coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued a "buy" rating for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Monday, November 25th.
Read Our Latest Stock Analysis on ORKA
Oruka Therapeutics Price Performance
Shares of Oruka Therapeutics stock traded down $0.51 on Monday, reaching $21.22. 83,530 shares of the stock were exchanged, compared to its average volume of 68,024. Oruka Therapeutics has a twelve month low of $18.20 and a twelve month high of $53.88. The company has a market capitalization of $742.70 million, a price-to-earnings ratio of -3.47 and a beta of 0.87. The company has a 50 day simple moving average of $25.60.
Institutional Trading of Oruka Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new stake in Oruka Therapeutics during the 3rd quarter worth approximately $343,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $1,037,000. Wellington Management Group LLP acquired a new position in Oruka Therapeutics during the third quarter worth $2,013,000. Janus Henderson Group PLC purchased a new position in Oruka Therapeutics in the third quarter worth $5,840,000. Finally, Redmile Group LLC acquired a new stake in Oruka Therapeutics in the third quarter valued at $10,091,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.
About Oruka Therapeutics
(
Get Free ReportARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
See Also
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
